Cambrex Opens New Stability Storage Facility

Today, Cambrex announced its stability storage business, Q1 Scientific, and opened a new cGMP facility in Durham, North Carolina, expanding its capacity for environmentally controlled stability storage services to North America's pharmaceutical, medical device, and life sciences industries.

Strategically located in the Research Triangle Park (RTP) region, the new state-of-the-art temperature-controlled and monitored storage facility provides 7 ICH stability chambers, covering a range of conditions from 40°C to ultra-low (-70°C/-80°C) storage conditions. The RTP facility will provide same-day and next-day delivery across the United States.

Tom Loewald, Cambrex CEO, stated, “After acquiring Q1 Scientific in 2022, we have strategically expanded our footprint to best serve our clients worldwide. This first North American facility opening marks an important milestone in the growth of Q1 Scientific.”

Q1 Scientific’s expansion complements its existing facilities in Waterford, Ireland and Liège, Belgium, and is co-located within Cambrex’s existing analytical services site in Durham.

Stephen Delaney, Managing Director of Q1 Scientific, added, “With the capabilities and expertise co-located in Durham, we can now deliver services beyond stability storage, such as stability testing and other analytical services for clinical and commercial products.”

Cambrex continues to expand its capabilities and capacity across its North American and European network to meet the growing demand for outsourced drug development and manufacturing services.

Company

Logo:

Cambrex Corporation

One Meadowlands Plaza
07073 East Rutherford
US

Company contact







Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read